Payment overview · 2025
General Payments
$294.37
16 reported records · 7 companies
Healthcare provider profile · identity verified
Steven Michael Crow, MD
Allopathic & Osteopathic Physicians|Family Medicine · LUBBOCK, TX · NPI 1740244078
Verified facts
What the public records show
CMS Open Payments records show Steven Michael Crow, MD received $294.37 in general payments during 2025 across 16 reported records.
GlaxoSmithKline, LLC. accounted for 48.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $143.96 | 48.9% | 10 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $38.76 | 13.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.81 | 9.1% | 1 | 2025 |
| Alvogen Inc | Unresolved — no canonical attribution shown | $24.45 | 8.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.91 | 8.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.97 | 7.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.51 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $294.37 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $128.35 | 7 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $38.76 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $35.00 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $26.81 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Alvogen Inc | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.61 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 856 | 230 |
| Levothyroxine Sodium | Levothyroxine Sodium | 819 | 201 |
| Lisinopril | Lisinopril | 523 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 382 | 98 |
| Metformin Hcl | Metformin Hcl | 322 | 91 |
| Prednisone | Prednisone | 292 | 208 |
| Potassium Chloride | Potassium Chloride | 271 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 268 | 74 |
| Escitalopram Oxalate | Escitalopram Oxalate | 264 | 68 |
| Cefdinir | Cefdinir | 262 | 210 |
| Meloxicam | Meloxicam | 259 | 92 |
| Doxycycline Hyclate | Doxycycline Hyclate | 257 | 184 |
| Pantoprazole Sodium | Pantoprazole Sodium | 248 | 80 |
| Fluticasone Propionate | Fluticasone Propionate | 228 | 89 |
| Gabapentin | Gabapentin | 221 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 54 |
| Alendronate Sodium | Alendronate Sodium | 202 | 54 |
| Alprazolam | Alprazolam | 198 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 192 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 191 | 25 |
| Omeprazole | Omeprazole | 172 | 50 |
| Tramadol Hcl | Tramadol Hcl | 162 | 45 |
| Furosemide | Furosemide | 150 | 54 |
| Irbesartan | Irbesartan | 144 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 44 |
| Allopurinol | Allopurinol | 128 | 35 |
| Sertraline Hcl | Sertraline Hcl | 120 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 52 |
| Cephalexin | Cephalexin | 117 | 88 |
| Ezetimibe | Ezetimibe | 116 | 31 |
| Glipizide Er | Glipizide | 110 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 107 | 37 |
| Montelukast Sodium | Montelukast Sodium | 107 | 28 |
| Carvedilol | Carvedilol | 106 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 23 |
| Donepezil Hcl | Donepezil Hcl | 101 | 26 |
| Mounjaro | Tirzepatide | 95 | 16 |
| Simvastatin | Simvastatin | 95 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 22 |
| Losartan Potassium | Losartan Potassium | 92 | 27 |
| Azithromycin | Azithromycin | 91 | 81 |
| Bupropion Xl | Bupropion Hcl | 90 | 23 |
| Trazodone Hcl | Trazodone Hcl | 85 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 81 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 23 |
| Celecoxib | Celecoxib | 79 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 19 |
| Fluconazole | Fluconazole | 76 | 55 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 76 | 44 |
| Valacyclovir | Valacyclovir Hcl | 75 | 37 |
| Azelastine Hcl | Azelastine Hcl | 72 | 21 |
| Ozempic | Semaglutide | 69 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 16 |
| Finasteride | Finasteride | 66 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 16 |
| Estradiol | Estradiol | 62 | 18 |
| Ketoconazole | Ketoconazole | 54 | 27 |
| Ondansetron Odt | Ondansetron | 54 | 36 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 14 |
| Spironolactone | Spironolactone | 51 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 31 |
| Meclizine Hcl | Meclizine Hcl | 47 | 33 |
| Paxlovid | Nirmatrelvir/Ritonavir | 47 | 47 |
| Eliquis | Apixaban | 45 | 16 |
| Nystatin | Nystatin | 45 | 25 |
| Tresiba Flextouch U-100 | Insulin Degludec | 45 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 43 | 11 |
| Propranolol Hcl | Propranolol Hcl | 42 | 12 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 40 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | suppressed |
| Amoxicillin | Amoxicillin | 38 | 25 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 31 |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 14 |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | suppressed |
| Premarin | Estrogens, Conjugated | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 24 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 20 |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Tobramycin | Tobramycin | 21 | 20 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 20 | 20 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | 12 |
| Breyna | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Captopril | Captopril | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 11 |
| Ofloxacin | Ofloxacin | 14 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Yuvafem | Estradiol | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Wellbutrin Sr | Bupropion Hcl | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $294.37 · 16 records | GlaxoSmithKline, LLC. | AREXVY, FARXIGA, INSPIRE, Ozempic, Rybelsus, SHINGRIX, TERIPARATIDE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error